Midbrain dopamine neurons:: Projection target determines action potential duration and dopamine D2 receptor inhibition

被引:187
|
作者
Margolis, Elyssa B. [1 ]
Mitchell, Jennifer M. [1 ]
Ishikawa, Junko [1 ]
Hjelmstad, Gregory O. [1 ,2 ,3 ]
Fields, Howard L. [1 ,2 ,3 ]
机构
[1] Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Emeryville, CA 94608 USA
[2] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Wheeler Ctr Neurobiol Addict, San Francisco, CA 94143 USA
来源
JOURNAL OF NEUROSCIENCE | 2008年 / 28卷 / 36期
关键词
dopamine; ventral tegmental area; nucleus accumbens; amygdala; D-2; receptor; kappa-opioid;
D O I
10.1523/JNEUROSCI.1526-08.2008
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Broad action potentials (APs) and dopamine (DA) D2 receptor (D2R)-mediated inhibition are widely used to identify midbrain DA neurons. However, when these measures are taken alone they do not predict DA content in ventral tegmental area (VTA) neurons. In fact, some VTA neuronal properties correlate better with projection target than neurotransmitter content. Here we report that amygdala (AMYG)-projecting VTA DA neurons have brief APs and lack D2R agonist (quinpirole; 1 mu M) autoinhibition. However, they are hyperpolarized by both the GABA(B) agonist baclofen ( 1 mu M) and the kappa-opioid receptor agonist U69593 [(+)-(5 alpha,7 alpha,8 beta)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]benzeneacetamide; 1 mu M]. Furthermore, we show that accurate prediction of DA content in VTA neurons is possible when the projection target is known: in both nucleus accumbens- and AMYG-projecting neural populations, AP durations are significantly longer in DA than non-DA neurons. Among prefrontal cortex-projecting neurons, quinpirole sensitivity, but not AP duration, is a predictor of DA content. Therefore, in the VTA, AP duration and inhibition by D2R agonists may be valid markers of DA content in neurons of known projection target.
引用
收藏
页码:8908 / 8913
页数:6
相关论文
共 50 条
  • [21] Mutational and biochemical analysis of dopamine in dystonia -: Evidence for decreased dopamine D2 receptor inhibition
    Todd, RD
    Perlmutter, JS
    MOLECULAR NEUROBIOLOGY, 1998, 16 (02) : 135 - 147
  • [22] Positive Reinforcement Mediated by Midbrain Dopamine Neurons Requires D1 and D2 Receptor Activation in the Nucleus Accumbens
    Steinberg, Elizabeth E.
    Boivin, Josiah R.
    Saunders, Benjamin T.
    Witten, Ilana B.
    Deisseroth, Karl
    Janak, Patricia H.
    PLOS ONE, 2014, 9 (04):
  • [23] A fresh look at cortical dopamine D2 receptor expressing neurons
    Quintana, Clementine
    Beaulieu, Jean-Martin
    PHARMACOLOGICAL RESEARCH, 2019, 139 : 440 - 445
  • [24] Functional Mapping of Cortical Dopamine D2 Receptor Expressing Neurons
    Khlghatyan, Jivan
    Quintana, Clementine
    Parent, Martin
    Beaulieu, Jean-Martin
    NEUROPSYCHOPHARMACOLOGY, 2017, 42 : S560 - S560
  • [25] Main interactions of dopamine and risperidone with the dopamine D2 receptor
    Martinez, Ana
    Garcia-Gutierrez, Ponciano
    Zubillaga, Rafael A.
    Garza, Jorge
    Vargas, Rubicelia
    PHYSICAL CHEMISTRY CHEMICAL PHYSICS, 2021, 23 (26) : 14224 - 14230
  • [26] Dopamine D2 receptor and obesity
    Chen, JS
    LANCET, 2001, 357 (9271): : 1883 - +
  • [27] Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine
    Tuppurainen, Heli
    Kuikka, Jyrki T.
    Viinamaki, Heimo
    Husso, Minna
    Tiihonen, Jari
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2009, 63 (04) : 529 - 537
  • [28] The potential of dopamine receptor D2 (DRD2) as a therapeutic target for tackling pancreatic cancer
    Bakadlag, Rowa
    Jandaghi, Pouria
    Hoheisel, Joerg D.
    Riazalhosseini, Yasser
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (05) : 365 - 367
  • [29] Mechanism of action of quetiapine is via modulation of dopamine at the D2 receptor
    Goldstein, J
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 168 - 168
  • [30] THE EFFECT OF CONTINUOUS AND REPEATED ADMINISTRATION OF D1 DOPAMINE RECEPTOR ANTAGONIST ON MIDBRAIN DOPAMINE NEURONS
    WACHTEL, SR
    WHITE, FJ
    NEUROCHEMISTRY INTERNATIONAL, 1992, 20 : S129 - S133